Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Startseite
  2. Aktien
  3. Kanada
  4. Toronto Stock Exchange
  5. HLS Therapeutics Inc.
  6. News
  7. Andere Sprachen
    HLS   CA40390B1094

HLS THERAPEUTICS INC.

(A2JGH0)
  Bericht
Verzögert Toronto Stock Exchange  -  22:00 29.09.2022
9.030 CAD   +0.33%
28.09.HLS Therapeutics Inc. : Stifel GMP bleibt bei seiner Kaufempfehlung
MM
12.08.HLS Therapeutics Inc. : Stifel GMP gibt eine Kauf-Bewertung ab
MM
11.08.HLS Therapeutics meldet Q2-Umsatz von 15,5 Millionen US-Dollar
MT
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über HLS THERAPEUTICS INC.
15.09.HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on September 22, 2022
09.09.HLS Therapeutics to Present at the H.C. Wainwright Global Investment Conference
11.08.Transcript : HLS Therapeutics Inc., Q2 2022 Earnings Call, Aug 11, 2022
11.08.HLS Therapeutics Reports Q2 Revenue US$15.5 Million
11.08.Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 4, ..
11.08.Earnings Flash (HLS.TO) HLS THERAPEUTICS Reports Q2 Revenue US$15.5 Million
11.08.HLS Therapeutics Announces Q2 Fiscal 2022 Financial Results
11.08.HLS Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months En..
11.08.HLS Therapeutics Inc. Declares Dividend, Payable on December 15, 2022
11.08.North American Morning Briefing: Post-CPI Mood -2-
02.08.HLS Therapeutics Brief: Announcing that Vascepa Now Reimbursed by..
02.08.HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan
28.07.HLS Therapeutics to Host Q2 Fiscal 2022 Financial Results Conference Call
26.07.HLS Announces that Vascepa is now reimbursed by Ontario's Provincial Drug Plan
25.07.HLS Therapeutics Says Vascepa is Now Reimbursed by Ontario's Provincial Drug Plan
25.07.HLS Therapeutics Inc. Enters into a Product Listing Agreement with Ontario
25.07.HLS Therapeutics Brief: Announcing that Vascepa is Now Reimbursed..
25.07.HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan
22.06.HLS Therapeutics Obtains Public Reimbursement for Vascepa in New Brunswick and with oth..
22.06.HLS Therapeutics Inc. Obtains Public Reimbursement for Vascepa® in New Brunswick and wi..
22.06.HLS Therapeutics Brief: Obtains Public Reimbursement for Vascepa ..
22.06.HLS Therapeutics Obtains Public Reimbursement for Vascepa® in New Brunswick and with ot..
20.06.HLS Therapeutics Reports Annual Meeting Results
17.06.HLS Therapeutics Reports Annual Meeting Results
17.06.Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call
15.06.HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 22, 2022
01.06.HLS Therapeutics to Present at the 2022 Jefferies Healthcare Conference
24.05.HLS Therapeutics Executive Chair Bill Wells Retires, Gubitz to Become Board Chair
24.05.HLS Therapeutics Executive Chairman and Co-Founder Bill Wells to Retire
24.05.HLS Therapeutics Inc. Announces Board Changes
24.05.HLS Therapeutics Obtains Public Reimbursement for Vascepa in Quebec
24.05.HLS Therapeutics Brief: Obtains Public Reimbursement for Vascepa ..
24.05.HLS Therapeutics Obtains Public Reimbursement for Vascepa® in Quebec
24.05.Hls Therapeutics Obtains Public Reimbursement for Vascepa in Quebec
05.05.HLS Therapeutics Narrows Q1 Loss as Revenue Grows; Declares Dividend
05.05.Transcript : HLS Therapeutics Inc., Q1 2022 Earnings Call, May 05, 2022
05.05.Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 4, ..
05.05.HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
05.05.Earnings Flash (HLS.TO) HLS THERAPEUTICS Posts Q1 Revenue US$14.6 Million
05.05.HLS Therapeutics Announces Q1 Fiscal 2022 Financial Results
05.05.HLS Therapeutics Inc. Declares Dividend, Payable on September 15, 2022
28.04.HLS Therapeutics to Host Q1 Fiscal 2022 Financial Results Conference Call
27.04.HLS Therapeutics completes negotiations with pCPA for Vascepa
27.04.Amarin partner hls therapeutics completes reimbursement negotiations with pan-canadian ..
26.04.Transcript : HLS Therapeutics Inc. - Special Call
26.04.HLS Therapeutics Completes Negotiations with pCPA for Vascepa, Updates Peak-Year Sales ..
26.04.HLS Therapeutics Brief: Says Peak-year estimates expected to be r..
26.04.HLS Therapeutics Brief: Updates Its Peak-year Sales Estimate to $..
26.04.HLS Therapeutics completes negotiations with pCPA for Vascepa®
26.04.HLS Therapeutics Brief: Says Completed Negotiations with pCPA for..
26.04.HLS Therapeutics Completes Letter of Intent With Canada Alliance on Vascepa
25.04.HLS Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conferen..
17.03.Transcript : HLS Therapeutics Inc., Q4 2021 Earnings Call, Mar 17, 2022
17.03.HLS Therapeutics Reports Q4 Loss of US$0.13 Per Share; Updates on Vascepa
17.03.Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 4, ..
17.03.Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 5, ..
17.03.HLS Therapeutics Brief: Says "Is in the Final Stages" of the Proc..
17.03.HLS Therapeutics Brief: Q4 2021 Revenue of US$15.7 million, Adjus..
17.03.HLS Therapeutics Announces Q4 and Fiscal 2021 Financial Results
17.03.HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 202..
17.03.HLS Therapeutics Inc. Declares Dividend for the Year 2021, Payable on June 15, 2022
17.03.HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31..
14.03.HLS Therapeutics to Host Q4 & Fiscal 2021 Financial Results Conference Call
12.01.HLS Therapeutics to Present at the Sidoti Investor Conference
2021HLS Therapeutics Establishes Automatic Share Purchase Plan
2021HLS Therapeutics Establishes Automatic Share Purchase Plan
2021HLS Therapeutics to Present at Stifel GMP's Future of Healthcare Conference
2021HLS Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
2021Transcript : HLS Therapeutics Inc., Q3 2021 Earnings Call, Nov 04, 2021
2021HLS Therapeutics Inc. announces an Equity Buyback for 1,622,559 shares, representing 5%..
2021Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 5, ..
2021HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
2021Earnings Flash (HLS.TO) HLS THERAPEUTICS Posts Q3 Revenue US$15.06 Million
2021HLS Therapeutics Announces Q3 Fiscal 2021 Financial Results
2021HLS Therapeutics Inc. Declares Dividend on Common Shares, Payable on March 15, 2022
2021North American Morning Briefing: Stocks Futures -2-
2021HLS Therapeutics Inc's Equity Buyback announced on November 5, 2020, has expired.
2021HLS Therapeutics Inc. authorizes a Buyback Plan.
2021Hls Therapeutics : to Host Q3 2021 Financial Results Conference Call
2021Hls Therapeutics : to Participate in Two Virtual Non-Deal Roadshows
2021HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa in Canada
2021HLS Therapeutics : Details Promotional Agreement with Pfizer for Vascep..
2021Hls Therapeutics : Announces Promotional Agreement with Pfizer for Vascepa® in Canada
2021HLS Therapeutics Inc. Announces Promotional Agreement with Pfizer for Vascepa in Canada
2021HLS Therapeutics : Q2 Net Loss Narrows YoY to US$0.07 Per Share; Revenu..
2021Transcript : HLS Therapeutics Inc., Q2 2021 Earnings Call, Aug 05, 2021
2021Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 5, ..
2021Hls Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 20..
2021HLS Therapeutics : Earnings Flash (HLS.TO) HLS THERAPEUTICS Posts Q2 Re..
2021Hls Therapeutics : Announces Second Quarter Fiscal 2021 Financial Results
2021HLS Therapeutics Inc. Declares Dividend, Payable on December 15, 2021
2021Hls Therapeutics : to Present at the Canaccord Genuity 41st Annual Growth Conference
2021Hls Therapeutics : to Host Q2 2021 Financial Results Conference Call
2021Hls Therapeutics : Reports Annual Meeting Results
2021Hls Therapeutics : Reports Annual Meeting Results
2021HLS Therapeutics Inc. Announces Board Appointments
2021Hls Therapeutics : to Participate in Virtual Non-Deal Roadshow on June 16, 2021
2021Hls Therapeutics : to Participate in Virtual Non-Deal Roadshow on June 10, 2021
2021Hls Therapeutics : Announces Participation at Upcoming Investor Conferences
2021Transcript : HLS Therapeutics Inc., Q1 2021 Earnings Call, May 06, 2021
Anstehende Termine für HLS THERAPEUTICS INC.